The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Research Report 2025
Synopsis
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is maternal inheritance, or mitochondrial inheritance, caused by mutations in mitochondrial DNA11778, 14484 or 3460.It's a common type of inherited optic neuropathy. Related drugs include oxygen, ribonucleic acid, arginine, aidibenzoquinone, vitamin C, unoprostol.
The global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) include Alkeus Pharmaceuticals, Amgen, Biovista, Editas Medicine, GenSight Biologics, Ixchel Pharma, Khondrion, Mitotech and ProQR Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy).
Report Scope
The Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkeus Pharmaceuticals
Amgen
Biovista
Editas Medicine
GenSight Biologics
Ixchel Pharma
Khondrion
Mitotech
ProQR Therapeutics
Sanofi
Spark Therapeutics
Stealth BioTherapeutics
Usher Syndrome
Segment by Type
Dominant Optic Atrophy
Recessive Optic Atrophy
Segment by Application
Hospitals
Eye Clinics
Medical Research Institute
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is maternal inheritance, or mitochondrial inheritance, caused by mutations in mitochondrial DNA11778, 14484 or 3460.It's a common type of inherited optic neuropathy. Related drugs include oxygen, ribonucleic acid, arginine, aidibenzoquinone, vitamin C, unoprostol.
The global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) include Alkeus Pharmaceuticals, Amgen, Biovista, Editas Medicine, GenSight Biologics, Ixchel Pharma, Khondrion, Mitotech and ProQR Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy).
Report Scope
The Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alkeus Pharmaceuticals
Amgen
Biovista
Editas Medicine
GenSight Biologics
Ixchel Pharma
Khondrion
Mitotech
ProQR Therapeutics
Sanofi
Spark Therapeutics
Stealth BioTherapeutics
Usher Syndrome
Segment by Type
Dominant Optic Atrophy
Recessive Optic Atrophy
Segment by Application
Hospitals
Eye Clinics
Medical Research Institute
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Overview
1.1 Product Overview and Scope of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
1.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Type
1.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Value Comparison by Type (2024-2030)
1.2.2 Dominant Optic Atrophy
1.2.3 Recessive Optic Atrophy
1.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Application
1.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Eye Clinics
1.3.4 Medical Research Institute
1.3.5 Other
1.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size Estimates and Forecasts
1.4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue 2019-2030
1.4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales 2019-2030
1.4.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Competition by Manufacturers
2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Price by Manufacturers (2019-2024)
2.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), Product Type & Application
2.7 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Competitive Situation and Trends
2.7.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Players Market Share by Revenue
2.7.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Retrospective Market Scenario by Region
3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2019-2030
3.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2019-2024
3.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2025-2030
3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region: 2019-2030
3.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region: 2019-2024
3.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region: 2025-2030
3.4 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Facts & Figures by Country
3.4.1 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2019-2030)
3.4.3 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Facts & Figures by Country
3.5.1 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2019-2030)
3.5.3 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Facts & Figures by Country
3.6.1 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2019-2030)
3.6.3 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Facts & Figures by Country
3.7.1 Latin America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2019-2030)
3.7.3 Latin America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Facts & Figures by Country
3.8.1 Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2019-2030)
4.1.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2019-2024)
4.1.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2025-2030)
4.1.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Type (2019-2030)
4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2019-2030)
4.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2019-2024)
4.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2025-2030)
4.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Type (2019-2030)
4.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2019-2030)
5.1.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2019-2024)
5.1.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2025-2030)
5.1.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Application (2019-2030)
5.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2019-2030)
5.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2019-2024)
5.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2025-2030)
5.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Application (2019-2030)
5.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Alkeus Pharmaceuticals
6.1.1 Alkeus Pharmaceuticals Corporation Information
6.1.2 Alkeus Pharmaceuticals Description and Business Overview
6.1.3 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.1.5 Alkeus Pharmaceuticals Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Biovista
6.3.1 Biovista Corporation Information
6.3.2 Biovista Description and Business Overview
6.3.3 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.3.5 Biovista Recent Developments/Updates
6.4 Editas Medicine
6.4.1 Editas Medicine Corporation Information
6.4.2 Editas Medicine Description and Business Overview
6.4.3 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.4.5 Editas Medicine Recent Developments/Updates
6.5 GenSight Biologics
6.5.1 GenSight Biologics Corporation Information
6.5.2 GenSight Biologics Description and Business Overview
6.5.3 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.5.5 GenSight Biologics Recent Developments/Updates
6.6 Ixchel Pharma
6.6.1 Ixchel Pharma Corporation Information
6.6.2 Ixchel Pharma Description and Business Overview
6.6.3 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.6.5 Ixchel Pharma Recent Developments/Updates
6.7 Khondrion
6.6.1 Khondrion Corporation Information
6.6.2 Khondrion Description and Business Overview
6.6.3 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.7.5 Khondrion Recent Developments/Updates
6.8 Mitotech
6.8.1 Mitotech Corporation Information
6.8.2 Mitotech Description and Business Overview
6.8.3 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.8.5 Mitotech Recent Developments/Updates
6.9 ProQR Therapeutics
6.9.1 ProQR Therapeutics Corporation Information
6.9.2 ProQR Therapeutics Description and Business Overview
6.9.3 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.9.5 ProQR Therapeutics Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 Spark Therapeutics
6.11.1 Spark Therapeutics Corporation Information
6.11.2 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Description and Business Overview
6.11.3 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.11.5 Spark Therapeutics Recent Developments/Updates
6.12 Stealth BioTherapeutics
6.12.1 Stealth BioTherapeutics Corporation Information
6.12.2 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Description and Business Overview
6.12.3 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.12.5 Stealth BioTherapeutics Recent Developments/Updates
6.13 Usher Syndrome
6.13.1 Usher Syndrome Corporation Information
6.13.2 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Description and Business Overview
6.13.3 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
6.13.5 Usher Syndrome Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Chain Analysis
7.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Production Mode & Process
7.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Marketing
7.4.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Channels
7.4.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors
7.5 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers
8 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Dynamics
8.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends
8.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Drivers
8.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Challenges
8.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
